Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients (Q46188727)

20 December 2017

title

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients (English)

1 reference

20 December 2017

1 reference

1 reference

lymphoblastic leukemia

1 reference

Jonathan K Armstrong

1

1 reference

20 December 2017

Georg Hempel

2

1 reference

20 December 2017

Susanne Koling

3

1 reference

20 December 2017

Linda S Chan

4

1 reference

20 December 2017

Timothy Fisher

5

1 reference

20 December 2017

Herbert J Meiselman

6

1 reference

20 December 2017

George Garratty

7

1 reference

20 December 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

20 December 2017

published in

Cancer

1 reference

20 December 2017

volume

110

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

103-111

1 reference

20 December 2017

Pegaspargase: a review of clinical studies

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Peginterferon alfa-2a: a review of approved and investigational uses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Pegylated interferons for the treatment of chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Chemistry for peptide and protein PEGylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Effective drug delivery by PEGylated drug conjugates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Pegylation: engineering improved pharmaceuticals for enhanced therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Bioconjugation in pharmaceutical chemistry.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Stabilization of substances in circulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Effects of PEG conjugation on insulin properties

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Gene expression analysis of purified hematopoietic stem cells and committed progenitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Use of ?-asparaginase in childhood ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Comparative pharmacokinetic studies of three asparaginase preparations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Antibodies Neutralizing Peginterferon Alfa during Retreatment of Hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22739

7 January 2021

Identifiers

DOI

10.1002/CNCR.22739

1 reference

20 December 2017

PubMed ID

17516438

1 reference

20 December 2017